Skip to content
Screener

Shattuck Labs, Inc. STTK Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
$269M+399%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$331M-209%
Amgen logo
AmgenAMGN
-$73M+81.5%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$2.73M-8.3%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$4.82M-237%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$98K+45.9%

Segments

By segment

See full
Reportable Segment$1M+74.7%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$694.34M+1,861%
Enterprise value$633.72M-5,344%
P/S694.3×+683×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
RevenueThree Months Ended June 30, 2026 / $Three Months Ended June 30, 2026 / —Three Months Ended June 30, 2025 / $Three Months Ended June 30, 2025 / —Six Months Ended June 30, 2026 / $Six Months Ended June 30, 2026 / —Six Months Ended June 30, 2025 / $Six Months Ended June 30, 2025 / —
Other income (expense)
Interest income1,0298041,8321,416
Other expense(26)(230)(52)(155)
Total other income1,0035741,7801,261
Net loss$$(15,152)$$(12,458)$$(29,919)$$(26,160)
Unrealized (loss) gain on investments(63)1(69)(1)
Comprehensive loss$$(15,215)$$(12,457)$$(29,988)$$(26,161)
Net loss per share – basic and diluted$$(0.12)$$(0.24)$$(0.25)$$(0.51)

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s other income (expense)?
Shattuck Labs, Inc. (STTK) reported other income (expense) of $1M in Q2 2026.
How has Shattuck Labs, Inc.'s other income (expense) changed year-over-year?
Shattuck Labs, Inc.'s other income (expense) increased by 74.7% year-over-year, from $574K to $1M.
What is the long-term trend for Shattuck Labs, Inc.'s other income (expense)?
Over 3 years (2022 to 2025), Shattuck Labs, Inc.'s other income (expense) has grown at a 24.9% compound annual growth rate (CAGR), from $1.38M to $2.7M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Shattuck Labs, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude